September 2, 2020
A team of scientists from the University of Michigan Rogel Cancer Center has developed the first drug-like compounds to inhibit a key family of enzymes whose malfunction is associated with several types of cancer, including an aggressive form of childhood leukaemia. The enzymes — known as the nuclear receptor-binding SET domain […]